Skip to main content
. 2020 Dec 22;23(5):722–730. doi: 10.1093/europace/euaa378

Table 1.

Demographics and baseline characteristics

FIRMap (N = 24) Conventional (N = 27) All subjects (N = 51)
Age (years), mean ± SD (n), median [IQR] 62 ± 11.4 (24), 65 [33–78] 65 ± 9.7 (27), 68 [48–78] 63 ± 10.6 (51), 65 [33–78]
Sex, male 14/24 (58.3%) 15/27 (55.6%) 29/51 (56.9%)
BMI (kg/m2), mean ± SD (n), median [IQR] 27 ± 6.2 (24), 25 [18–39] 28 ± 5.5 (26), 27 [19–43] 28 ± 5.8 (50), 26 [18–43]
EHRA class
Class I 2/24 (8.3%) 0/27 (0.0%) 2/51 (3.9%)
Class II 8/24 (33.3%) 7/27 (25.9%) 15/51 (29.4%)
Class III 14/24 (58.3%) 18/27 (66.7%) 32/51 (62.7%)
Class IV 0/24 (0.0%) 1/27 (3.7%) 1/51 (2.0%)
Unknown 0/24 (0.0%) 1/27 (3.7%) 1/51 (2.0%)
Medical history
Arterial hypertension 11/20 (55.0%) 13/21 (61.9%) 24/41 (58.5%)
Coronary artery disease 8/20 (40.0%) 8/21 (38.1%) 16/41 (39.0%)
Chronic renal insufficiency 2/20 (10.0%) 3/21 (14.3%) 5/41 (12.2%)
Anti-arrhythmic use at baseline (%)
Amiodarone 2/24 (8.3%) 0/25 (0.0%) 2/49 (4.1%)
Dronedarone 0/24 (0.0%) 0/25 (0.0%) 0/49 (0.0%)
Flecainide 4/24 (16.7%) 7/25 (28.0%) 11/49 (22.4%)
Propafenone 1/24 (4.2%) 0/25 (0.0%) 1/49 (2.0%)
Sotalol 0/24 (0.0%) 2/25 (8.0%) 2/49 (4.1%)
Left atrial diameter (mm); mean ± SD (n), median [IQR] 44 ± 5.5 (24), 43 [36–55] 44 ± 7.3 (23), 42 [32–67] 44 ± 6.4 (47), 42 [32–67]

IQR, interquartile range.